Stock Events

Stock Events

Acticor Biotech

0

0

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Bristol-Myers Squibb

Bristol-Myers Squibb is a leading biopharmaceutical company that competes with Acticor Biotech in the development of treatments for cardiovascular diseases, including thrombosis, which is a focus area for Acticor Biotech.

Pfizer is a global pharmaceutical corporation with a broad portfolio that includes drugs for cardiovascular diseases, directly competing with Acticor Biotech's thrombosis and related cardiovascular treatments.

Novo Nordisk is involved in the development of treatments for blood and endocrine disorders, including conditions related to thrombosis and cardiovascular diseases, making it a competitor to Acticor Biotech.

Sanofi operates globally in the pharmaceutical sector, with a focus on cardiovascular diseases among others, competing with Acticor Biotech in the area of thrombosis treatment.

AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a strong emphasis on cardiovascular, renal, and metabolism medication, competing in the same therapeutic areas as Acticor Biotech.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division Janssen, develops medications for various diseases, including cardiovascular conditions, making it a competitor to Acticor Biotech.

Amgen focuses on human therapeutics, with products targeting cardiovascular diseases among others, competing with Acticor Biotech in the development of innovative treatments.

Merck & Co., Inc. is known for its wide range of pharmaceutical products, including those for cardiovascular health, directly competing with Acticor Biotech's focus on thrombosis and related conditions.

Eli Lilly and Company is a global pharmaceutical company with a focus on several therapeutic areas, including cardiovascular diseases, competing with Acticor Biotech in research and development of treatments.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of medicines for serious medical conditions, including cardiovascular diseases, competing with Acticor Biotech in innovation and market share.

About

Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.

Show more...

CEO

Dr. Gilles Avenard M.D.

Employees

31

Country

France

ISIN

FR0014005OJ5

WKN

000A3C6GM

Listings

0 Comments

Share your thoughts

FAQ

What is Acticor Biotech stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Acticor Biotech stocks are traded under the ticker 7V7.STU.

How many employees does Acticor Biotech have?▼

As of September 05, 2026, the company has 31 employees.

In which sector is Acticor Biotech located?▼

Acticor Biotech operates in the Health & Wellness sector.

When did Acticor Biotech complete a stock split?▼

Acticor Biotech has not had any recent stock splits.

Where is Acticor Biotech headquartered?▼

Acticor Biotech is headquartered in Paris, France.